DIMENSION

• Research type

  Research Study

• Full title

  A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease

• IRAS ID

  1004868

• Contact name

  Robert Solinga

• Contact email

  robert.solinga@sagerx.com

• Sponsor organisation

  Sage Therapeutics, Inc.

• Eudract number

  2021-005577-16

• ISRCTN Number

  ISRCTN17896603

• Clinicaltrials.gov Identifier

  NCT05107128

• Research summary

  The DIMENSION Study is evaluating the safety and efficacy of an investigational oral drug in adults with [early] Huntington’s disease (HD). This drug is being tested to see if it can specifically target cognitive symptoms associated with HD.
  The study lasts up to 20 weeks and includes 9 visits to the study office.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  22/LO/0177

• Date of REC Opinion

  5 May 2022

• REC opinion

  Further Information Favourable Opinion